CN115645537A - Application of FcRn inhibitor in preparation of medicine for inhibiting recurrence of autoimmune disease - Google Patents
Application of FcRn inhibitor in preparation of medicine for inhibiting recurrence of autoimmune disease Download PDFInfo
- Publication number
- CN115645537A CN115645537A CN202211311655.1A CN202211311655A CN115645537A CN 115645537 A CN115645537 A CN 115645537A CN 202211311655 A CN202211311655 A CN 202211311655A CN 115645537 A CN115645537 A CN 115645537A
- Authority
- CN
- China
- Prior art keywords
- fcrn
- group
- ulcerative colitis
- use according
- recurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 title claims abstract description 54
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 26
- 239000003112 inhibitor Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 74
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 74
- 210000002966 serum Anatomy 0.000 claims abstract description 35
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 9
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000002757 inflammatory effect Effects 0.000 claims description 14
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 12
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 101150050927 Fcgrt gene Proteins 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000033789 Neuroendocrine tumor of the colon Diseases 0.000 claims description 3
- 208000036438 well differentiated low or intermediate grade tumor neuroendocrine tumor of the colon Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 150000003384 small molecules Chemical group 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 claims 1
- 108091006374 cAMP receptor proteins Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 abstract description 55
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 abstract description 16
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 abstract description 16
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 abstract description 16
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 abstract description 16
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 abstract description 16
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 abstract description 16
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 abstract description 16
- 230000002829 reductive effect Effects 0.000 abstract description 16
- 201000001021 colon neuroendocrine neoplasm Diseases 0.000 abstract description 6
- 229940121657 clinical drug Drugs 0.000 abstract description 4
- 102100033717 Retroviral-like aspartic protease 1 Human genes 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 45
- 238000005070 sampling Methods 0.000 description 19
- 102100036407 Thioredoxin Human genes 0.000 description 15
- 229940027941 immunoglobulin g Drugs 0.000 description 14
- 108010074051 C-Reactive Protein Proteins 0.000 description 12
- 102100032752 C-reactive protein Human genes 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000002759 woven fabric Substances 0.000 description 8
- 102000003896 Myeloperoxidases Human genes 0.000 description 7
- 108090000235 Myeloperoxidases Proteins 0.000 description 7
- 230000008485 antagonism Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 5
- 229920003045 dextran sodium sulfate Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 3
- 101710180313 Protease 3 Proteins 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 108010068617 neonatal Fc receptor Proteins 0.000 description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108091006110 nucleoid-associated proteins Proteins 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101150094373 Padi4 gene Proteins 0.000 description 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention provides application of an FcRn inhibitor in preparation of a medicine for inhibiting recurrence of autoimmune diseases, and belongs to the field of pharmacy. The invention discovers for the first time that the FcRn target is closely related to the recurrence of ulcerative colitis, and the anti-FcRn antibody is given to antagonize the FcRn function, so that the clearance of serum ANCA of a rat can be accelerated, the formation of colon NET can be reduced, the ulcerative colitis can be effectively treated, and the recurrence of the ulcerative colitis can be effectively inhibited; however, SASP, which is a clinical drug for treating ulcerative colitis, does not antagonize FcRn function and does not inhibit the recurrence of ulcerative colitis. Therefore, the FcRn inhibitor including the anti-FcRn antibody has wide application prospect in preparing the medicine for inhibiting the recurrence of autoimmune diseases such as ulcerative colitis.
Description
Technical Field
The invention belongs to the field of pharmacy, and particularly relates to an application of an FcRn inhibitor in preparation of a medicine for inhibiting recurrence of autoimmune diseases.
Background
Autoimmune diseases refer to diseases caused by the body's immune response to autoantigens resulting in damage to its tissues or organs. Autoimmune diseases are classified into: (1) Organ-specific autoimmune diseases, characterized in that pathological lesions and dysfunctions of tissues and organs are limited to only one organ to which antibodies or sensitized lymphocytes are directed, such as Ulcerative Colitis (UC), crohn's Disease (CD), and the like; (2) Systemic autoimmune diseases, which are systemic multiple organ damages caused by the reason that antigen-antibody complexes are widely deposited on blood vessel walls, such as systemic lupus erythematosus, rheumatoid arthritis and the like.
UC is a chronic nonspecific inflammatory bowel disease, and pathological changes are mostly seen in large intestine mucous membrane and submucosa and are distributed in a continuous and diffuse manner. The clinical manifestations are abdominal pain, persistent or recurrent diarrhea, mucopurulent bloody stool, malabsorption, etc. The clinical treatment process of UC has a long course, patients may relapse due to the stimulation of various physiological and pathological factors or environmental factors, and the problem that UC is easy to relapse also becomes a key factor that UC is difficult to control or cure. At present, the understanding about the pathogenesis of UC mainly considers that UC is induced by inflammatory reaction of intestinal mucosa due to the influence of intestinal flora disorder, autoimmune regulation imbalance, genetic factors and the like. The autoimmune disorder is one of the key factors for the generation and development of UC, and a large amount of neutrophil infiltration appears in the colon part with pathological inflammation in the early stage of the UC generation, and a phenomenon of Neutrophil Extracellular Trap (NET) is generated. NET formation is considered to be a key factor in the persistence of UC inflammation. NET is generated to break neutrophils, release various inflammatory factors and neutrophilic particles, such as Myeloperoxidase (MPO) and protease 3 (PR3) and the like, which are respectively combined with DNA in chromatin to form a complex with antigenicity, the complex is then recognized by abnormally activated T cells, a cellular immune pathway is activated to generate autoantibodies, namely anti-neutrophil cytoplasmic antibodies (ANCA), and the ANCA can be combined with the MPO or PR3 on the surface of the neutrophil membrane to activate and chemotaxis, so that NET-ANCA circulation is repeatedly formed. ANCA, as an intermediate link in maintaining this cycle, is clinically thought to be highly correlated with UC disease progression and risk of recurrence.
ANCAs belong to the IgG class of autoantibodies, the transport of which in vivo is mediated primarily by the neonatal Fc receptor (FcRn). The physiological function of FcRn is exerted by binding to its ligand, which is mainly known as IgG and serum albumin, and after binding to the Fc fragment of IgG or the DIII domain of albumin, fcRn can be protected from lysosomal degradation, thereby significantly prolonging its half-life. Therefore, fcRn plays a crucial role in the in vivo clearance of autoimmune or pathogenic IgG. At present, the research on FcRn as a target for treating autoimmune diseases is concerned by applying the effect of FcRn on the half-life of IgG, and part of protein polypeptide FcRn inhibitors enter the clinical experiment stage.
The Chinese patent application No. 2016800405166 discloses a humanized affinity matured anti-FcRn antibody with a specific sequence and the use of the anti-FcRn antibody with the specific sequence in the treatment of autoimmune diseases including ulcerative colitis, crohn's disease, systemic lupus erythematosus and rheumatoid arthritis. However, the treatment of autoimmune diseases and the suppression of recurrence of autoimmune diseases are two distinct effects. For the treatment of UC, the frequency of disease recurrence in patients is more important factor in selecting treatment regimens (see "(consensus opinion on diagnosis and treatment of inflammatory bowel disease (2018, beijing) section interpretation of ulcerative colitis, hui-bai, 11/5/2018, volume 33, phase 11.) at present, drugs that can effectively inhibit the recurrence of autoimmune diseases including ulcerative colitis are only rarely reported and cannot meet clinical needs.
Disclosure of Invention
The invention aims to provide application of an FcRn inhibitor in preparing a medicament for inhibiting the recurrence of autoimmune diseases.
The invention provides application of an FcRn inhibitor in preparing a medicament for inhibiting the recurrence of autoimmune diseases.
Further, the autoimmune diseases include ulcerative colitis, crohn's disease, systemic lupus erythematosus, rheumatoid arthritis.
Further, the autoimmune disease is ulcerative colitis.
Further, the medicament is a medicament for treating autoimmune diseases.
Further, the drug is a drug that reduces serum ANCA levels, a drug that reduces serum indices of inflammation, and/or a drug that reduces colonic NET formation.
Further, the inflammation index includes TNF-alpha, IL-1 beta and CRP.
Further, the FcRn inhibitor is a small molecule FcRn inhibitor or a protein polypeptide FcRn inhibitor.
Further, the protein polypeptide FcRn inhibitor is an anti-FcRn antibody.
Furthermore, the medicament is a preparation prepared by taking an FcRn inhibitor as an active ingredient and adding pharmaceutically acceptable auxiliary materials.
Further, the preparation is an oral preparation, an injection preparation or a transdermal administration preparation.
In the present invention, fcRn is an abbreviation for neonatal Fc receptor (neonatal Fc receptor).
An FcRn inhibitor refers to a drug capable of targeted inhibition/antagonism of FcRn function or expression, and an anti-FcRn antibody is a known FcRn inhibitor.
According to the invention, the FcRn target point is closely related to the recurrence of ulcerative colitis for the first time, and the anti-FcRn function is antagonized by intravenous injection of anti-Fc-mAb, so that the clearance of rat serum ANCA can be accelerated, the formation of colon NET can be reduced, the ulcerative colitis can be effectively treated, and the recurrence of the ulcerative colitis can be effectively inhibited; however, SASP, which is a clinical drug for treating ulcerative colitis, does not antagonize FcRn function and does not inhibit the recurrence of ulcerative colitis.
The FcRn inhibitor including the anti-FcRn antibody has wide application prospect in preparing the medicine for inhibiting the recurrence of autoimmune diseases such as ulcerative colitis.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1: animal experimental roadmap.
FIG. 2: serum IgG concentration measurement results of NC group, UC group, SASP group, FC group, and DFC group. * /#/Δ and #/##represent p <0.05 and p <0.01, respectively; n.s means that the difference is not statistically significant (p > 0.05).
FIG. 3: the results of measurement of serum ANCA concentrations in the NC group, UC group, SASP group, FC group, and DFC group. * /#, # and # represent p <0.05, respectively, p-woven fabrics 0.01, p-woven fabrics 0.001; n.s means that the difference is not statistically significant (p > 0.05).
FIG. 4: NC group, UC group, SASP group, FC group, DFC group colon NET related protein (NAPs, including PAD4, MPO and NE). The expression level of NAPs and the expression level of the internal reference protein GAPDH are normalized to obtain the relative expression quantity. Data are presented as mean ± standard deviation (n = 6). #, and # are respectively represented by p <0.05, p- < -0.01, p < -0.001; n.s means that the difference is not statistically significant (p > 0.05).
FIG. 5: (a) Statistical analysis results of rat DAI and HS in NC group, UC group, SASP group, FC group, DFC group, data are expressed as mean ± standard deviation (n = 6). # and #/#indicatep <0.01 and p <0.001, respectively; n.s means that the difference is not statistically significant (p > 0.05). (b) And (c), (d), (e) and (f) are representative histopathology images of rats of NC, UC, SASP, FC and DFC groups in sequence.
FIG. 6: the serum TNF-alpha concentrations of rats in the NC group, the UC group, the SASP group, the FC group and the DFC group. Data are presented as mean ± standard deviation (n = 6). * /#, #/# Δ Δ and # Δ represent p <0.05, respectively, p-woven fabrics 0.01, p-woven fabrics 0.001; n.s means that the difference is not statistically significant (p > 0.05).
FIG. 7: the serum IL-1 beta concentration of rats in NC group, UC group, SASP group, FC group and DFC group. Data are presented as mean ± standard deviation (n = 6). * /#, # and # represent p <0.05, p-woven fabrics 0.01, respectively, p-woven fabrics 0.001; n.s means that the difference is not statistically significant (p > 0.05).
FIG. 8: serum CRP concentrations in rats of NC group, UC group, SASP group, FC group, and DFC group. Data are presented as mean ± standard deviation (n = 6). * /#, # and # represent p <0.05, respectively, p-woven fabrics 0.01, p-woven fabrics 0.001; n.s means that the difference is not statistically significant (p > 0.05).
FIG. 9: serum concentrations of ANCA (a), TNF-. Alpha. (b), IL-1. Beta. (c), CRP (d) at sampling points of N3 and N4 in UC group, SASP group, FC group, and DFC group. Data are presented as mean ± standard deviation (n = 6).
Diamond-solid and diamond-solid represent p <0.05 and p <0.01, respectively; n.s means that the difference is not statistically significant (p > 0.05).
Detailed Description
The raw materials and equipment used in the invention are known products and are obtained by purchasing commercial products.
Example 1: in vivo experiments for inhibition of ulcerative colitis recurrence by anti-rat FcRn antibodies
1. Experimental medicine
Anti-rat FcRn antibody (anti-Fc-mAb) was purchased from Bio X cell, usa under the following commercial information: 4.32mg/mL (1.2 mL), cat #: BE0222, lot #:680320D1.
Sulfasalazine (SASP), a clinical drug for the treatment of ulcerative colitis, was purchased from milnacle biotechnology limited with a purity of >97%, cas:599-79-1, lot.
2. Experimental methods
The experiment was carried out with reference to the scheme shown in FIG. 1. 30 SD rats of about 8-12 weeks of age were selected, weighed 250-300g, and randomly divided into 5 groups (n =6 per group) and designated as NC, UC, SASP, FC, DFC groups. NC group is normal control group; the other four groups were dosed as follows: the UC group rats were given purified water, the SASP group rats were given sulfasalazine (SASP, 400mg/kg, p.o/day), the FC group rats were given anti-rat FcRn antibody (anti-Fc-mAb, 80. Mu.g/kg, i.v/7 days), and the DFC group rats were given anti-rat FcRn antibody (anti-Fc-mAb, 160. Mu.g/kg, i.v/7 days). Rats in UC group, SASP group, FC group and DFC group are given 3% (w/v) dextran sodium sulfate (DDS) for 7 days, and pure water is used for replacing 7 days as a remission stage; 3% (w/v) DSS solution was given on day 15 for 3 days as the first recurrent inflammatory phase (IRP-1) and replaced with pure water for 7 days. Followed by feeding 3% DSS for 7 days as a second recurrent inflammatory phase (IRP-2); finally, pure water is replaced until the experiment is finished. Before the start of dosing, on day 7 after dosing, on day 14 after dosing, on day 21 after dosing, each group of rats had blood samples (200 μ L) taken from the orbit into microcentrifuge tubes (designated N1, N2, N3, N4 in order); on day 28 post-dose, rats were anesthetized by intraperitoneal injection of 50% urethane (3 mL/kg), blood samples were collected from the heart into microcentrifuge tubes (noted N5), and the colon was collected for biochemical and histopathological analysis.
Disease symptom changes are monitored in the experimental process, and the concentration of serum anti-neutrophil cytoplasmic antibodies (ANCA), immunoglobulin G (IgG), interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha) and C-reactive protein (CRP) and the expression level of protein related to colon Neutrophil Extracellular Trap (NET) are determined.
3. Results of the experiment
Serum IgG levels are an indicator of antagonism of FcRn function. FIG. 2 shows the monitoring results of serum IgG level of rats in each group. It can be seen that, in the three sampling points of N3, N4 and N5, the water level of serum IgG of rats in the DFC group is significantly reduced compared to that in the UC group, and the serum IgG level of rats in the FC group at a smaller dosage is significantly reduced compared to that in the UC group only in the two sampling points of N4 and N5; the serum IgG level of the rats in the SASP group has no obvious change compared with that in the UC group in all sampling points; furthermore, in the N5 sampling point, the FC group was substantially comparable to the DFC group serum IgG levels. The experimental result shows that 28 days of continuous SASP administration can not affect the FcRn transport function in rats; however, the rat anti-Fc-mAb was administered intravenously at 160. Mu.g/kg for two doses to show significant FcRn functional antagonism; significant antagonism of FcRn function was also observed following intravenous administration of three doses of anti-Fc-mAb to rats at a dose of 80 μ g/kg.
FIG. 3 shows the monitoring results of serum ANCA levels of rats in each group. It can be seen that, starting from the N3 sampling point, serum ANCA levels of rats in the SASP group, FC group and DFC group are significantly reduced compared with those in the UC group. Since serum ANCA levels correlate with the degree of UC inflammation and serum ANCA levels decrease in the presence of inflammatory remission, the serum ANCA levels decreased in the SASP group rats due to the anti-inflammatory effects of the SASP itself, although FcRn transport function was not altered. It is noted that serum ANCA levels of rats in DFC group were further significantly reduced at three sampling points N3, N4 and N5 compared to SASP group, and serum ANCA levels of rats in FC group were further significantly reduced at two sampling points N4 and N5 compared to SASP group. This is because the action of antagonizing FcRn accelerates clearance of serum ANCA, and the antagonism of FcRn function exerted by the DFC group and FC group further reduces serum ANCA levels in rats, further alleviating inflammation in rats.
The formation of NET is a key factor for the persistence of the ulcerative colitis inflammation, and is closely related to the recurrence of the ulcerative colitis. FIG. 4 shows the expression of colon NET associated proteins (PAD 4, MPO, NE) in rats in each group, and it can be seen that after the four doses of anti-Fc-mAb are given (28 days of SASP), the levels of colon NET associated proteins (PAD 4, MPO and NE) in the FC group and the DFC group are significantly reduced compared with the UC control group; compared with the SASP group, the levels of colonic NET associated proteins (PAD 4, MPO and NE) were further reduced in the FC group and DFC group, and the differences were statistically significant. The anti-Fc-mAb can obviously reduce the formation of NET at the colon part of a rat and is beneficial to inhibiting the recurrence of ulcerative colitis; and compared with SASP, the anti-Fc-mAb has obviously improved effect of reducing NET formation at the colon part of a rat, and is more favorable for inhibiting the recurrence of ulcerative colitis.
Disease Activity Index (DAI) and Histopathological Score (HS) are commonly used indicators for determining the status of ulcerative colitis. FIG. 5 shows the result of statistical analysis of DAI and HS in various groups of rats. The results show that after the four doses of anti-Fc-mAb are finished (28 days of SASP administration), the DAI and HS of FC group and DFC group are obviously reduced compared with UC control group; the DAI and HS of the FC and DFC groups were further reduced compared to the SASP group, and the difference was statistically significant. The anti-Fc-mAb can obviously reduce disease activity index and histopathological score of rats and can effectively treat ulcerative colitis; and, compared with SASP, the anti-Fc-mAb has significantly enhanced effects on reducing disease activity index and histopathological score in rats, and has significantly enhanced effects on treating ulcerative colitis.
FIGS. 6-8 show the results of monitoring inflammation-related indexes (IRIs) such as TNF- α, IL-1 β, and CRP in rat serum during the experiment. It can be seen that from the N3 sampling point, the serum TNF-alpha, IL-1 beta and CRP levels of the rats in the SASP group, FC group and DFC group are all significantly reduced compared with those in the UC group. It is noted that the serum TNF-alpha, IL-1 beta and CRP levels of rats in the DFC group were further significantly reduced at three sampling points N3, N4 and N5 compared with those in the SASP group, and the serum TNF-alpha, IL-1 beta and CRP levels of rats in the FC group were further significantly reduced at two sampling points N4 and N5 compared with those in the SASP group. This is because the antagonism of FcRn function exerted by the DFC and FC groups further reduced rat serum TNF- α, IL-1 β and CRP levels, further alleviating rat inflammation.
In this experiment, the first simulated recurrent inflammatory phase (IRP-1) preceded by the N3 sampling point, and the N4 sampling point was within the second simulated recurrent inflammatory phase (IRP-2). By combining the monitoring results of serum TNF-alpha, IL-1 beta and CRP of rats in each experimental group of three sampling points of N3, N4 and N5, the inventor finds that intravenous injection of anti-Fc-mAb has a UC treatment effect which is obviously improved compared with SASP administration in the inflammatory relapse period.
By further transversely comparing the detection results of ANCA, TNF-alpha, IL-1 beta and CRP of rat sera among the experimental groups of the N3 and N4 sampling points (fig. 9), it can be found that the indexes of the N4 sampling point rat sera of the UC group and the SASP group are obviously increased compared with the N3 sampling point, while the indexes of the N4 sampling point rat sera of the FC group and the DFC group are not obviously different from the N3 sampling point, along with repeated stimulation of an exogenous inflammatory factor (DSS solution in the experiment). The SASP can not resist the inflammatory relapse of the ulcerative colitis caused by the exogenous inflammatory factors, and the antagonism of the FcRn function by intravenous injection of anti-Fc-mAb can effectively resist the inflammatory relapse of the ulcerative colitis caused by the exogenous inflammatory factors.
Through the experiment, the invention discovers that the FcRn target point is closely related to the recurrence of the ulcerative colitis for the first time, and the anti-FcRn function is antagonized by intravenous injection of anti-Fc-mAb, so that the clearance of rat serum ANCA can be accelerated, the formation of colon NET can be reduced, the ulcerative colitis can be effectively treated, and the recurrence of the ulcerative colitis can be effectively inhibited; however, administration of SASP failed to antagonize FcRn function and also failed to inhibit recurrence of ulcerative colitis.
In conclusion, the invention provides the application of the FcRn inhibitor in preparing the medicine for inhibiting the recurrence of the autoimmune disease. The invention discovers that the FcRn target point is closely related to the recurrence of the ulcerative colitis for the first time, and the anti-FcRn antibody is given to antagonize the FcRn function, so that the recurrence of the ulcerative colitis can be effectively inhibited; however, SASP, which is a clinical drug for treating ulcerative colitis, does not antagonize FcRn function and does not inhibit the recurrence of ulcerative colitis. Therefore, the FcRn inhibitor including the anti-FcRn antibody has wide application prospect in preparing the medicine for inhibiting the recurrence of autoimmune diseases such as ulcerative colitis.
Claims (10)
- Use of an fcrn inhibitor for the manufacture of a medicament for inhibiting recurrence of an autoimmune disease.
- 2. Use according to claim 1, characterized in that: the autoimmune diseases include ulcerative colitis, crohn's disease, systemic lupus erythematosus, and rheumatoid arthritis.
- 3. Use according to claim 2, characterized in that: the autoimmune disease is ulcerative colitis.
- 4. Use according to any one of claims 1 to 3, characterized in that: the medicament is a medicament for treating autoimmune diseases.
- 5. Use according to any one of claims 1 to 3, characterized in that: the drug is a drug that reduces serum ANCA levels, a drug that reduces serum inflammatory indicators, and/or a drug that reduces colonic NET formation.
- 6. Use according to claim 5, characterized in that: the inflammatory markers include TNF-alpha, IL-1 beta, and CRP.
- 7. Use according to any one of claims 1 to 6, characterized in that: the FcRn inhibitor is a small molecule FcRn inhibitor or a protein polypeptide FcRn inhibitor.
- 8. Use according to claim 7, characterized in that: the protein polypeptide FcRn inhibitor is an anti-FcRn antibody.
- 9. Use according to any one of claims 1 to 8, characterized in that: the medicament is a preparation prepared by taking an FcRn inhibitor as an active ingredient and adding pharmaceutically acceptable auxiliary materials.
- 10. Use according to claim 9, characterized in that: the preparation is an oral preparation, an injection preparation or a transdermal administration preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211311655.1A CN115645537A (en) | 2022-10-25 | 2022-10-25 | Application of FcRn inhibitor in preparation of medicine for inhibiting recurrence of autoimmune disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211311655.1A CN115645537A (en) | 2022-10-25 | 2022-10-25 | Application of FcRn inhibitor in preparation of medicine for inhibiting recurrence of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115645537A true CN115645537A (en) | 2023-01-31 |
Family
ID=84990824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211311655.1A Pending CN115645537A (en) | 2022-10-25 | 2022-10-25 | Application of FcRn inhibitor in preparation of medicine for inhibiting recurrence of autoimmune disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115645537A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100048488A1 (en) * | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| CN101815723A (en) * | 2007-08-09 | 2010-08-25 | 森托尼克斯制药有限公司 | immunomodulatory peptides |
| CN102149729A (en) * | 2008-04-25 | 2011-08-10 | 戴埃克斯有限公司 | Antibodies against FcRn and use thereof |
| CN106103476A (en) * | 2013-12-24 | 2016-11-09 | 阿尔金-X有限公司 | FcRn antagonist and using method |
| CN114716550A (en) * | 2015-05-12 | 2022-07-08 | Synt免疫公司 | Humanized affinity matured anti-FcRn antibodies |
-
2022
- 2022-10-25 CN CN202211311655.1A patent/CN115645537A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101815723A (en) * | 2007-08-09 | 2010-08-25 | 森托尼克斯制药有限公司 | immunomodulatory peptides |
| CN102149729A (en) * | 2008-04-25 | 2011-08-10 | 戴埃克斯有限公司 | Antibodies against FcRn and use thereof |
| US20100048488A1 (en) * | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| CN106103476A (en) * | 2013-12-24 | 2016-11-09 | 阿尔金-X有限公司 | FcRn antagonist and using method |
| CN114716550A (en) * | 2015-05-12 | 2022-07-08 | Synt免疫公司 | Humanized affinity matured anti-FcRn antibodies |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Body-Malapel et al. | The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for Inflammatory Bowel Diseases | |
| CN104271156B (en) | The antibody of anti-GELB | |
| Jahagirdar et al. | RVX-297, a BET bromodomain inhibitor, has therapeutic effects in preclinical models of acute inflammation and autoimmune disease | |
| Wang et al. | MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53 | |
| Korbet et al. | Immune complex deposition and coronary vasculitis in systemic lupus erythematosus: report of two cases | |
| Savin et al. | Multiple targets for novel therapy of FSGS associated with circulating permeability factor | |
| EP2882456B1 (en) | Use of il-20 antagonists for treating liver diseases | |
| JP6923215B2 (en) | Anti-HTLV-1 agent, HTLV-1-related myelopathy (HAM / TSP) therapeutic agent | |
| JP2021522266A (en) | ABCB5 Ligand and Substrate | |
| Bergheim et al. | Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carrierss⃞ | |
| Wang et al. | N‐methyl‐4‐isoleucine cyclosporine attenuates CCl4‐induced liver fibrosis in rats by interacting with cyclophilin B and D | |
| Del Moral et al. | Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits. | |
| Hunter et al. | Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis | |
| Kim et al. | PBT-6, a novel PI3KC2γ inhibitor in rheumatoid arthritis | |
| CA2758829C (en) | Method of treating demyelinating disease | |
| EP3380615B1 (en) | Il-34 antisense oligonucleotides and methods of using same | |
| AU2020367414A1 (en) | Therapy for diabetes using stem cell migration agent | |
| Liu et al. | Protective effects of the soluble receptor for advanced glycation end‐products on Pyroptosis during myocardial ischemia‐reperfusion | |
| TWI654996B (en) | Microrna let-7 and transforming growth factor beta receptor iii axis as target for cardiac injuries | |
| EP2984108B1 (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer | |
| Neale et al. | Spontaneous glomerulonephritis in rabbits: role of a glomerular capillary antigen | |
| CN115645537A (en) | Application of FcRn inhibitor in preparation of medicine for inhibiting recurrence of autoimmune disease | |
| Barker et al. | The mammalian target of rapamycin contributes to synovial fibroblast pathogenicity in rheumatoid arthritis | |
| WO2020194317A1 (en) | Method of treating lipid-related disorders | |
| CN114895032A (en) | Application of novel SRSF1 shear factor small molecule inhibitor Okanin and pharmaceutical composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230131 |
|
| RJ01 | Rejection of invention patent application after publication |